Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iMMagine-3: Anitocabtagene Autoleucel vs Standard of Care in Relapsed/Refractory Multiple Myeloma
jRCT2043240170Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Jun 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Anitocabtagene autoleucel with Standard of care therapy (2 arms). Primary endpoints: Progression-Free Survival (PFS) and MRD-negative Complete Response at 9 Months. Started Jun 2025; status: active, not recruiting.
02
Drugs
anitocabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2043240170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2043240170.